Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis.


Journal

Journal of musculoskeletal & neuronal interactions
ISSN: 1108-7161
Titre abrégé: J Musculoskelet Neuronal Interact
Pays: Greece
ID NLM: 101084496

Informations de publication

Date de publication:
01 09 2020
Historique:
entrez: 4 9 2020
pubmed: 4 9 2020
medline: 28 9 2021
Statut: ppublish

Résumé

To examine the effect of denosumab administration in the peripheral blood white cell population, to further elucidate a plausible pathophysiological link between denosumab and osteonecrosis of the jaw. Thirty women with osteoporosis, after denosumab treatment were included. Peripheral blood samples were obtained prior to and 48-72 hours following denosumab administration. Flow cytometry gated at the monocyte population for CD14/CD23/CD123/CD16 stainings were performed. We were able to record a number of changes in the monocyte populations between baseline and after denosumab administration. Most importantly, in the monocyte populations we were able to detect statistically significant increased populations of CD14+/CD23+ (p=0.044), CD14-/CD23+ (p=0.044), CD14+/CD123+ (p=0.011), CD14+/CD123- (p=0.011) and CD14-/CD16+ (p=0.028). In contrast, statistically significant decreased populations of CD14-/CD123+ (p=0.034), CD14+/CD16+ (p=0.037) and CD14+/CD16- (p=0.014) were detected. Our results provide evidence supporting the hypothesis that denosumab administration modifies the monocyte mediated immune response in a manner similar to that of bisphosphonates. This may partly explain the trivial immunity changes recorded with denosumab.

Identifiants

pubmed: 32877971
pmc: PMC7493451

Substances chimiques

Bone Density Conservation Agents 0
Denosumab 4EQZ6YO2HI

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

339-346

Déclaration de conflit d'intérêts

The authors have no conflict of interest.

Références

Adv Pharm Bull. 2013;3(2):329-32
pubmed: 24312856
J Osteoporos. 2011 Feb 16;2011:147689
pubmed: 21403823
J Clin Oncol. 2009 Nov 10;27(32):5356-62
pubmed: 19805682
PLoS One. 2017 Jun 30;12(6):e0180568
pubmed: 28665971
Cochrane Database Syst Rev. 2014 Mar 14;(3):CD002010
pubmed: 24627308
Stem Cells Transl Med. 2014 Jan;3(1):128-34
pubmed: 24307697
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Mar;125(3):268-275
pubmed: 29325851
J Clin Oncol. 2008 Dec 20;26(36):5904-9
pubmed: 19018084
Am J Med. 2008 Jun;121(6):475-483.e3
pubmed: 18501224
Osteoporos Int. 2017 Mar;28(3):991-999
pubmed: 27858122
J Exp Med. 2011 Feb 14;208(2):227-34
pubmed: 21242295
Mol Pharm. 2017 Nov 6;14(11):4113-4120
pubmed: 28954509
Histopathology. 2018 May;72(6):914-922
pubmed: 29206281
Clin Oral Investig. 2015 Mar;19(2):497-508
pubmed: 24957986
Stem Cells Dev. 2013 Mar 15;22(6):985-97
pubmed: 23137270
J Bone Miner Res. 2012 Mar;27(3):694-701
pubmed: 22113951
J Bone Miner Res. 2015 Jan;30(1):3-23
pubmed: 25414052
Int J Oral Maxillofac Surg. 2013 Nov;42(11):1481-7
pubmed: 23932020
Immunity. 1995 Jul;3(1):119-25
pubmed: 7621072
Hum Immunol. 2003 Dec;64(12):1144-51
pubmed: 14630396
Osteoporos Int. 2014 Mar;25(3):1131-9
pubmed: 24343364
Blood. 2013 Oct 31;122(18):3138-48
pubmed: 24030378
J Immunol. 1995 Nov 15;155(10):4868-75
pubmed: 7594490
Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523
pubmed: 28546097
N Engl J Med. 2009 Aug 20;361(8):756-65
pubmed: 19671655
J Clin Oncol. 2008 Oct 1;26(28):4634-8
pubmed: 18574158
J Natl Cancer Inst. 2011 Feb 2;103(3):232-40
pubmed: 21189409
Osteoporos Int. 2011 Jan;22(1):369-70
pubmed: 20306021
PLoS One. 2016 May 10;11(5):e0154680
pubmed: 27163152
PLoS One. 2013 Jul 09;8(7):e67906
pubmed: 23874464
Anticancer Res. 2018 Jan;38(1):113-120
pubmed: 29277763
Immunol Today. 1993 Mar;14(3):121-5
pubmed: 7682078
J Allergy Clin Immunol. 2004 Aug;114(2):364-70
pubmed: 15316517
Front Bioeng Biotechnol. 2018 Feb 12;6:5
pubmed: 29484293
Am J Cardiol. 2014 Jun 1;113(11):1815-21
pubmed: 24837258
Clin Oral Investig. 2009 Dec;13(4):479-80; author reply 483-4
pubmed: 19680698
Blood. 1966 Sep;28(3):455-64
pubmed: 5918472
Horm Metab Res. 2009 Oct;41(10):721-9
pubmed: 19536731
Immunol Cell Biol. 2005 Oct;83(5):462-7
pubmed: 16174094
Expert Rev Anticancer Ther. 2009 Aug;9(8):1125-34
pubmed: 19671032
Sci Rep. 2016 Nov 11;6:36659
pubmed: 27834402
Lancet Oncol. 2010 Jun;11(6):513-4
pubmed: 20522379
Front Immunol. 2014 Sep 08;5:414
pubmed: 25250025
J Dent Res. 2015 Apr;94(4):534-9
pubmed: 25710950
Osteoporos Int. 2010 Nov;21(11):1963-4
pubmed: 20012939
Scand J Immunol. 2008 Feb;67(2):152-9
pubmed: 18201370
Oral Dis. 2012 Jan;18(1):85-95
pubmed: 21883710
J Oral Maxillofac Surg. 2009 Nov;67(11):2554
pubmed: 19837341
Front Biosci (Landmark Ed). 2009 Jan 01;14:2432-47
pubmed: 19273210
Clin Oral Investig. 2017 Jul;21(6):1979-1988
pubmed: 27796573
Bone. 2010 Feb;46(2):556; author reply 557-8
pubmed: 19796720

Auteurs

Athanassios Kyrgidis (A)

Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Pharmacology, Clinical Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Maria P Yavropoulou (MP)

Endocrinology Unit 1st Propaedeutic Department of Internal Medicine, LAIKO General Hospital of Athens, National and Kapodistrian University of Athens, UOA, Athens, Greece.

Petros Zikos (P)

Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Roza Lagoudaki (R)

Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece.

Jannis Tilaveridis (J)

Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Lambros Zouloumis (L)

Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH